18 results about "Pain disorder" patented technology

The invention provides a ziconotide nasal-brain delivery preparation which is high in brain targeting, safe and noninvasive and directly enters the brain through nasal administration. The nasal-brain delivery preparation comprises an active component ziconotide and an absorption enhancer, wherein the absorption enhancer is selected from one or more of dodecyl-beta-D-maltoside (DDM), menthol, hydroxypropyl-beta-cyclodextrin (HP-beta-CD), sodium glycocholate (SGC) and related derivatives thereof. The absorption enhancer with a specific type and content and the ziconotide cooperate and act together, so that the ziconotide bypasses a blood brain barrier, enters the brain through a nasal olfactory mucous membrane, forms a medicine storage bank in an olfactory bulb, is slowly released to the brain and keeps a long-term medicine effect, and therefore, a traditional ziconotide intrathecal administration mode is abandoned; the ziconotide nasal-brain administration mode is created, and the ziconotide nasal-brain administration method is a new-generation therapy for pain diseases related to the central nervous system.

This invention provides a polypeptide and its applications. The amino acid sequence of the polypeptide is shown in SEQ ID NO: 1 or SE ID NO: 2; the 12th amino acid in the amino acid sequence of the polypeptide is alanine or glutamic acid; the 19th amino acid in the amino acid sequence of the polypeptide is methionine or leucine; the 28th amino acid in the amino acid sequence of the polypeptide is lysine or isoleucine; and the 29th amino acid in the amino acid sequence of the polypeptide is selected from isoleucine, leucine, and tryptophan. The polypeptide provided by this invention has good analgesic function and can selectively inhibit the activation of Nav1.7 channels, thereby inhibiting pain, which has extremely important clinical significance for pain disorders.

The invention further relates to compounds, pharmaceutical compositions and methods for treating a subject for sexual function, such as sexual disorder or sexual dysfunction (SD), for inducing subject weight loss, for effectuating weight maintenance by a subject, whether or not the weight maintenance is used alone or in combination with a subject's weight loss, and / or for improving a subject's subjective state of well-being, self-esteem and / or self-confidence. Examples of SD contemplated by the present invention include but are not limited to female sexual disorder (FSD), female sexual arousal disorder (FSAD), female sexual interest / arousal disorder (FSIAD), female hypoactive sexual desire disorder (HSDD), female orgasmic disorder (FOD), female sexual pain disorder (FSPD), sexual interest arousal disorder (SIAD), male sexual disorder (MSD), male hypoactive sexual desire disorder (MSHDD), erectile dysfunction (ED), Pyronine's disease (PD), male premature ejaculation (MPE), male delayed ejaculation (MDE), male decreased libido (MDL), male dry orgasm (MDO).

Provided are methods to treat, ameliorate, prevent, reverse, decrease the severity and / or duration of a pain-associated disease or condition comprising administration of a pharmaceutically acceptable formulation comprising a glycolysis inhibitor.

This disclosure relates to heterocyclic compounds of Formula (I) as well as the preparation and use thereof. As contemplated herein, heterocyclic compounds of Formula (I) can be any one of a carbohydrate conjugate and an amino acid conjugate. The heterocyclic compounds of Formula (I) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate, and cocaine addiction, alcoholism, post-traumatic stress disorder (PTSD), and pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy.

Provided herein are prodrugs of phenylalanamines (e.g., magical phenylethylamines) incorporating a vitamin B6-based prodrug moiety (e.g., pyridoxal). Also provided are methods of making such compounds, pharmaceutical compositions thereof, and methods of use thereof, such as for the treatment of psychological health disorders, neurodegenerative disorders, pain disorders, and inflammation, including as part of adjuvant therapy as magical agents. (I) (I)

Provided in the present disclosure is a polypeptide and use thereof. The amino acid sequence of the polypeptide is as shown in SEQ ID NO: 1 or SE ID NO: 2; a 12th amino acid in the amino acid sequence of the polypeptide is alanine or glutamic acid, a 19th amino acid in the amino acid sequence of the polypeptide is methionine or leucine, a 28th amino acid in the amino acid sequence of the polypeptide is lysine or isoleucine, and a 29th amino acid in the amino acid sequence of the polypeptide is selected from any one of isoleucine, leucine and tryptophan. The polypeptide provided in the present disclosure provides good analgesic function and may selectively inhibit an activation of Nav1.7 channels, thereby inhibiting pain, which is of great clinical importance in pain disorders.

The present invention discloses nitrogen-containing heterocyclic derivatives of somatostatin receptor subtype 4 (SSTR4) small molecule agonists, as well as pharmaceutical compositions, preparation methods, and uses thereof. The nitrogen-containing heterocyclic derivatives of SSTR4 small molecule agonists are represented by formula (I), where specific substituents and definitions are as described herein. The nitrogen-containing heterocyclic derivatives of SSTR4 small molecule agonists exhibit good binding and agonist activity with SSTR4. Such compounds or pharmaceutical compositions thereof have great potential in the treatment and / or prevention of pain disorders associated with the SSTR4 receptor.

Disclosed are compounds having the formula (I), or an enantiomer, diastereomer, tautomer or atropisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, A, and n are defined herein. Also disclosed are methods of making such compounds, as well as pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of inflammatory disorders, allergic disorders, skin disorders, mast cell disorders, pain disorders, and pruritus disorders. (I)

This invention discloses an antibody targeting CGRP and its applications. The antibody or its antigen-binding portion comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises CDR-H1, CDR-H2, and CDR-H3, and the light chain variable region comprises CDR-L1, CDR-L2, and CDR-L3. This antibody can specifically bind to human and rat CGRP peptides and α / β subtype CGRP peptides with high affinity, blocking the binding of CGRP to its receptor CGRPR, reducing pain perception, and achieving the treatment of pain disorders such as migraines caused by CGRP. Furthermore, it can also relieve or treat hot flashes.

To provide cyclobutyl dihydroquinoline sulfonamide compounds.SOLUTION: The present invention provides a cyclobutyl dihydroquinoline sulfonamide compound of formula (I) in the figure, an enantiomer, diastereoisomer, atropisomer thereof, a mixture thereof, or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch.SELECTED DRAWING: None

The invention further relates to compounds, pharmaceutical compositions and methods for treating a subject for sexual function, such as sexual disorder or sexual dysfunction (SD), for inducing subject weight loss, for effectuating weight maintenance by a subject, whether or not the weight maintenance is used alone or in combination with a subject's weight loss, and / or for improving a subject's subjective state of well-being, self-esteem and / or self-confidence. Examples of SD contemplated by the present invention include but are not limited to female sexual disorder (FSD), female sexual arousal disorder (FSAD), female sexual interest / arousal disorder (FSIAD), female hypoactive sexual desire disorder (HSDD), female orgasmic disorder (FOD), female sexual pain disorder (FSPD), sexual interest arousal disorder (SIAD), male sexual disorder (MSD), male hypoactive sexual desire disorder (MSHDD), erectile dysfunction (ED), Pyronine's disease (PD), male premature ejaculation (MPE), male delayed ejaculation (MDE), male decreased libido (MDL), male dry orgasm (MDO).

The invention is based on the discovery of a novel compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Thus, the invention relates to novel lipopeptide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

The disclosure relates to the field of diseases caused by a lowered synaptic inhibition, preferably those that are caused by a diminished activity of the potassium (K) / chloride (Cl) Cotransporter 2 (KCC2). The disclosure involves oligonucleotides and the use thereof in RNA editing methods in targeting a variety of target adenosines in the human SLC12A5 transcript molecule that encodes KCC2. The transcript molecule is edited such that the resulting KCC2 protein has a gain-of-function and / or different function, for example reduced autoinhibition. The disclosure relates to oligonucleotides and their use in the treatment of neurodevelopment disorders, neuropsychiatric disorders, chronic pain disorders, and / or epilepsy.

Provided herein are substituted phenylalkylamine analogs, such as asymmetrically substituted 2, 5-dialkoxy phenylethylamine (e.g., wherein the 2-alkoxy and 5-alkoxy substituents are different). Also provided are methods of making such compounds, pharmaceutical compositions of such compounds, and methods of use thereof, such as for the treatment of mental health disorders, neurodegenerative disorders, pain disorders, and inflammation, including as part of a rosemary adjuvant therapy.

A chemical entity of Formula (I):wherein V, W, Y, and Z, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, cognitive disorders, neurodegenerative diseases, and trauma-dependent losses of function; enhancing the efficiency of cognitive and motor training, including in stroke or TBI rehabilitation; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, dermatological, inflammatory, and pain disorders.

The disclosure relates to the field of diseases caused by a lowered synaptic inhibition, preferably those that are caused by a diminished activity of the potassium (K) / chloride (Cl) Cotransporter 2 (KCC2). The disclosure involves oligonucleotides and the use thereof in RNA editing methods in targeting a variety of target adenosines in the human SLC12A5 transcript molecule that encodes KCC2. The transcript molecule is edited such that the resulting KCC2 protein has a gain-of-function and / or different function, for example reduced autoinhibition. The disclosure relates to oligonucleotides and their use in the treatment of neurodevelopment disorders, neuropsychiatric disorders, chronic pain disorders, and / or epilepsy.